Biology of anti-TNF agents in immune-mediated inflammatory diseases: Therapeutic implications

Immunotherapy

Volumn 8, Issue 12, 2016, Pages 1427-1436

  Levy, Roger A ^a   Guzman, Renato ^b   Castañeda Hernández, Gilberto ^c   Martinez Vazquez, Manuel ^d   Damian, Guilherme ^e   Cara, Carlos ^f  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b IDEARG   (Colombia)

^c DEPARTAMENTO DE FÍSICA   (Mexico)

^d HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^e UCB   (Brazil)

^f Preclinical CNS Research   (Belgium)

Author keywords

anti TNF; Fc receptor immunogenicity; immune mediated inflammatory diseases; monoclonal antibodies; pharmacokinetics

Indexed keywords

ADALIMUMAB; CD16 ANTIGEN; CERTOLIZUMAB PEGOL; ETANERCEPT; FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR IIB; FC RECEPTOR IV; GOLIMUMAB; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; INFLIXIMAB; MACROGOL; NEONATAL FC RECEPTOR; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; COMPLEMENT DEPENDENT CYTOTOXICITY; CROHN DISEASE; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG GLYCOSYLATION; DRUG HALF LIFE; DRUG PASYLATION; DRUG PEGYLATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TRANSFORMATION; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATORY DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SPONDYLARTHRITIS; ULCERATIVE COLITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); IMMUNE SYSTEM DISEASES; IMMUNOLOGY; INFLAMMATION; PROCEDURES;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOTHERAPY; INFLAMMATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85007247835     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt-2016-0067     Document Type: Review

References (53)

1. Kuek A, Hazleman BL, Ostör AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad. Med. J. 83, 251-260 (2007).
2. Blandizzi C, Gionchetti P, Armuzzi A et al. The role of tumour necrosis factor in the pathogenesis of immunemediated diseases. Int. J. Immunopathol. Pharmacol. 27(Suppl 1), 1-10 (2014).
3. Silva LC, Ortigosa LC, Benard G. Anti-TNF-? agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy 2(6), 817-833 (2010).
4. Armuzzi A, Lionetti P, Blandizzi C et al. Anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab. Int. J. Immunopathol. Pharmacol. 27(Suppl 1), 11-32 (2014).
5. Ordás I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin. Pharmacol. Ther. 91(4), 635-646 (2012).
6. Ho RJ, Chien JY. Drug delivery trends in clinical trials and translational medicine: growth in biologic molecule development and impact on rheumatoid arthritis, Crohn's disease, and colitis. J. Pharm. Sci. 101(8), 2668-2674 (2012).
7. Ternant D, Bejan-Angoulvant T, Passot C, Mulleman D, Paintaud G. Clinical pharmacokinetics and pharmacodynamics of monoclonal antibodies approved to treat rheumatoid arthritis. Clin. Pharmacokinet. 54(11), 1107-1123 (2015).
8. Raghavan M, Bjorkman PJ. Fc receptors and their interactions with immunoglobulins. Annu. Rev. Cell Dev. Biol. 12, 181-220 (1996).
9. Mould DR. Using pharmacometrics in the development of therapeutic biological agents. In: Pharmacometrics the Science of Quantitative Pharmacology. Ette E, Williams P (Eds). John Wiley & Sons Hoboken, USA (2007).
10. Pasut G. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol. BioDrugs 28(Suppl. 1), S15-S23 (2014).
11. Delgado Frias E, Diaz Gonzalez JF. Certolizumab pegol. Reumatol. Clin. 6(S3), S7-S11 (2011).
12. Kobak S. Efficacy and safety of adalimumab in a patient with ankylosing spondylitis on peritoneal dialysis. Rheumatol. Int. 32, 1785-1787 (2012).
13. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 84, 548-558 (2008).
14. European Medicines Agency (EMA). Summary of product characteristics. Enbrel. www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000262/WC500027361.pdf
15. Loyet KM, Deng R, Liang WC, Wu Y, Lowman HB, DeForge LE. Technology comparisons for anti-therapeutic antibody and neutralizing antibody assays in the context of an anti-TNF pharmacokinetic study. J. Immunol. Methods 345(1-2), 17-28 (2009).
16. Ng CM, Loyet KM, Iyer S, Fielder PJ, Deng R. Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-? IgG antibody in cynomolgus monkey. Eur. J. Pharm. Sci. 51, 51-58 (2014).
17. Monnet C, Jorieux S, Urbain R et al. Selection of IgG variants with increased FcRn binding using random and directed mutagenesis: impact on effector functions. Front. Immunol. 6, 39 (2015).
18. Dickinson BL, Claypool SM, D'Angelo JA et al. Ca2+-dependent calmodulin binding to FcRn affects immunoglobulin G transport in the transcytotic pathway. Mol. Biol. Cell 19, 414-423 (2008).
19. Smith KG, Clatworthy MR. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat. Rev. Immunol. 10(5), 328-333 (2010).
20. Van Lent P, Nabbe KC, Boross P et al. The inhibitory receptor FcgammaRII reduces joint inflammation and destruction in experimental immune complex-mediated arthritides not only by inhibition of FcgammaRI/III but also by efficient clearance and endocytosis of immune complexes. Am. J. Pathol. 163(5), 1839-1848 (2003).
21. Marks J. Antibody formation in myelomatosis. J. Clin. Pathol. 6(1), 62-63 (1953).
22. Andersen JT, Dalhus B, Viuff D et al. Extending serum halflife of albumin by engineering neonatal Fc receptor (FcRn) binding. J. Biol. Chem. 289(19), 13492-13502 (2014).
23. Sand KM, Dalhus B, Christianson GJ et al. Dissection of the neonatal Fc receptor (FcRn)-albumin interface using mutagenesis and anti-FcRn albumin-blocking antibodies. J. Biol. Chem. 289(24), 17228-17239 (2014).
24. Mihai S, Nimmerjahn F. The role of Fc receptors and complement in autoimmunity. Autoimmun. Rev. 12, 657-660 (2013).
25. Sánchez-Mejorada G, Rosales C. Signal transduction by immunoglobulin Fc receptors. J. Leukoc. Biol. 63(5), 521-533 (1998).
26. Debets JM, Van der Linden CJ, Dieteren IE, Leeuwenberg JF, Buurman WA. Fc-receptor cross-linking induces rapid secretion of tumor necrosis factor (cachectin) by human peripheral blood monocytes. J. Immunol. 141(4), 1197-1201 (1988).
27. Wojtal KA, Rogler G, Scharl M et al. Fc gamma receptor CD64 modulates the inhibitory activity of infliximab. PLoS One 7(8), e43361 (2012).
28. Mitoma H, Horiuchi T, Tsukamoto H et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 58(5), 1248-1257 (2008).
29. Nimmerjahn F, Lux A, Albert H et al. Fc?RIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc. Natl Acad. Sci. USA 107(45), 19396-19401 (2010).
30. Meroni PL, Valesini G. Tumour necrosis factor ? antagonists in the treatment of rheumatoid arthritis. An immunological perspective. BioDrugs 28(Suppl. 1), 5-13 (2014).
31. Dhodapkar MV, Dhodapkar KM, Li Z. Role of chaperones and FcgammaR in immunogenic death. Curr. Opin. Immunol. 20, 512-517 (2008).
32. Nimmerjahn F, Ravetc JV. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8, 34-47 (2008).
33. van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat. Rev. Rheumatol. 9(3), 164-172 (2013).
34. Mok CC, Tsai WC, Chen DY, Wei JC. Immunogenicity of anti-TNF biologic agents in the treatment of rheumatoid arthritis. Expert Opin. Biol. Ther. 16(2), 201-211 (2016).
35. Bendtzen K. Immunogenicity of anti-TNF-? biotherapies: II. Clinical relevance of methods used for anti-drug antibody detection. Front. Immunol. 6, 109 (2015).
36. Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease-algorithm for practical management. Aliment. Pharmacol. Ther. 43, 30-51 (2016).
37. van Schie KA, Wolbink GJ, Rispens T. Cross-reactive and pre-existing antibodies to therapeutic antibodies-effects on treatment and immunogenicity. MAbs 7, 662-671 (2015).
38. Deng R, Loyet KM, Lien S et al. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab. Dispos. 38, 600-605 (2010).
39. Gorevic PD. Rheumatoid factor, complement, and mixed cryoglobulinemia. Clin. Dev. Immunol. 2012, 439018 (2012).
40. Ordás I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 10(10), 1079-1087 (2012).
41. Nowakowska-Plaza A, Potaczek DP, Gluszko P, Undas A. Antibodies to N-homocysteinylated albumin and haemoglobin in patients with rheumatoid arthritis: a potential new marker of disease severity. Scand. J. Rheumatol. 43(1), 17-21 (2014).
42. Biancheri P, Brezski RJ, Di Sabatino A et al. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease. Gastroenterology 149(6), 1564-1574.e3 (2015).
43. Kolate A, Baradia D, Patil S, Vhora I, Kore G, Misra A. PEG-a versatile conjugating ligand for drugs and drug delivery systems. J. Control. Rel. 192, 67-81 (2014).
44. Turecek PL, Bossard MJ, Schoetens F, Ivens IA. PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs. J. Pharm. Sci. 105(2), 460-475 (2016).
45. Schellekens H, Hennink WE, Brinks V. The immunogenicity of polyethylene glycol: facts and fiction. Pharm. Res. 30, 1729-1734 (2013).
46. Verhoef JJ, Carpenter JF, Anchordoquy TJ, Schellekens H. Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics. Drug Discov. Today 19(12), 1945-1952 (2014).
47. Reichert C, Borchard G. Noncovalent PEGylation, an innovative subchapter in the field of protein modification. J. Pharm Sci. 105, 386-390 (2016).
48. Emery P, Vencovský J, Sylwestrzak A et al. A Phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann. Rheum. Dis. doi:10.1136/annrheumdis-2015-207588 (2015) (Epub ahead of print).
49. Moots RJ, Balsa A, Wolbink G. Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required. Ann. Rheum. Dis. 75(5), e24 (2016).
50. Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr. Opin. Biotechnol. 22(6), 868-876 (2011).
51. Schlapschy M, Binder U, Börger C et al. PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins. Protein Eng. Des. Sel. 26(8), 489-501 (2013).
52. Gregoriadis G, Jain S, Papaioannou I, Laing P. Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. Int. J. Pharm. 300(1-2), 125-130 (2005).
53. Larsen MT, Kuhlmann M, Hvam ML, Howard KA. Albumin-based drug delivery: harnessing nature to cure disease. Mol. Cell. Ther. 4, 3 (2016).